Role of topoisomerase mutations and efflux in fluoroquinolone resistance of Bacteroides fragilis clinical isolates and laboratory mutants

被引:31
|
作者
Ricci, V
Peterson, ML
Rotschafer, JC
Wexler, H
Piddock, LJV [1 ]
机构
[1] Univ Birmingham, Div Immun & Infect, Antimicrobial Agents Res Grp, Birmingham B15 2TT, W Midlands, England
[2] Univ Minnesota, Minneapolis, MN 55455 USA
[3] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA
关键词
D O I
10.1128/AAC.48.4.1344-1346.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Twelve laboratory mutants and 32 ciprofloxacin-resistant isolates of Bacteroides fragilis were examined for the mechanism(s) of fluoroquinolone resistance. Five mutants had mutations in gyrA. One mutant and two clinical isolates contained a mutation in gyrB. Eight mutants and five clinical isolates accumulated significantly less ciprofloxacin than did wild-type isolates; the mutants and clinical isolates were restored to wild-type characteristics when carbonyl cyanide m-chlorophenylhydrazone was used.
引用
收藏
页码:1344 / 1346
页数:3
相关论文
共 50 条
  • [41] INVITRO SUSCEPTIBILITY OF CLINICAL ISOLATES OF BACTEROIDES-FRAGILIS AND BACTEROIDES-THETAIOTAOMICRON IN JAPAN
    WATANABE, K
    UENO, K
    KATO, N
    MUTO, Y
    BANDOH, K
    TANAKA, Y
    JOTWANI, R
    GOTO, M
    SHIMADA, K
    SHIMIZU, K
    GOTO, S
    HARA, K
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1992, 11 (11) : 1069 - 1073
  • [42] Fluoroquinolone resistance associated with target mutations and active efflux in orophalyngeal colonizing isolates of viridans group streptococci
    Guerin, F
    Varon, E
    Hoï, AB
    Gutmann, L
    Podglajen, I
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (08) : 2197 - 2200
  • [43] Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae
    Weigel, LM
    Anderson, GJ
    Facklam, RR
    Tenover, FC
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (12) : 3517 - 3523
  • [44] Bacteroides fragilis BmeABC efflux systems additively confer intrinsic antimicrobial resistance
    Pumbwe, Lilian
    Ueda, Ohmi
    Yoshimura, Fuminobu
    Chang, Abraham
    Smith, Rachel L.
    Wexler, Hannah M.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (01) : 37 - 46
  • [45] Fluoroquinolone resistance in carbapenem-resistant Elizabethkingia anophelis: phenotypic and genotypic characteristics of clinical isolates with topoisomerase mutations and comparative genomic analysis
    Jian, Ming-Jr
    Cheng, Yun-Hsiang
    Chung, Hsing-Yi
    Cheng, Yu-Hsuan
    Yang, Hung-Yi
    Hsu, Chih-Sin
    Perng, Cherng-Lih
    Shang, Hung-Sheng
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (06) : 1503 - 1510
  • [46] Topoisomerase mutations in fluoroquinolone-resistant and methicillin-susceptible and -resistant clinical isolates of Staphylococcus aureus
    Kaatz, GW
    Seo, SM
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (01) : 197 - 198
  • [47] Antibiotic resistance and adhesion potential of Bacteroides fragilis clinical isolates from Cape Town, South Africa
    Galvao, B. P. G. V.
    Meggersee, R. L.
    Abratt, V. R.
    ANAEROBE, 2011, 17 (04) : 142 - 146
  • [48] Evaluation of the Disk Diffusion Test for Bacteroides fragilis Group Clinical Isolates
    Lee, Yangsoon
    Bae, Mi-Hyun
    Lee, Hyukmin
    Kim, Myungsook
    Lee, Kyungwon
    ANNALS OF LABORATORY MEDICINE, 2025, 45 (01) : 70 - 76
  • [49] CLINICAL IMPORTANCE OF CEFOXITIN-RESISTANT BACTEROIDES-FRAGILIS ISOLATES
    BIELUCH, VM
    CUCHURAL, GJ
    SNYDMAN, DR
    GORBACH, SL
    TALLY, FP
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1987, 7 (02) : 119 - 126
  • [50] INCREASING INCIDENCE OF CLINICAL ISOLATES OF BACTEROIDES-FRAGILIS RESISTANT TO CLINDAMYCIN
    SORIANO, F
    PONTE, C
    WILHELMI, I
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1984, 13 (04) : 395 - 395